{"filing":{"accession_number":"0001689548-26-000053","cik":"0001689548","ticker":"PRAX","company_name":"Praxis Precision Medicines, Inc.","form":"8-K","filing_date":"2026-06-01","report_date":null,"primary_document":"prax-20260601.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1689548/000168954826000053/prax-20260601.htm"},"events":[{"id":7978,"run_id":7004,"accession_number":"0001689548-26-000053","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.85,"summary":"The disclosure reports that the Phase 2/3 POWER1 study of vormatrigine failed to meet its primary success measure in focal onset seizures, though secondary measures were met. The Company is pausing enrollment in the POWER2 study to reassess the program. For a clinical-stage biopharmaceutical company, a failed primary endpoint in a pivotal Phase 2/3 trial represents a material setback to a key development program that would significantly affect investor assessment of the company's pipeline and prospects. This does not fit neatly into the specific event categories (not a restatement, impairment, or litigation), making \"other_material\" the appropriate classification.","company_name":"Praxis Precision Medicines, Inc.","ticker":"PRAX","filing_date":"2026-06-01","form":"8-K","submitted_at":null,"items":[{"id":3377,"accession_number":"0001689548-26-000053","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.85,"reasoning":"The disclosure reports that the Phase 2/3 POWER1 study of vormatrigine failed to meet its primary success measure in focal onset seizures, though secondary measures were met. The Company is pausing enrollment in the POWER2 study to reassess the program. For a clinical-stage biopharmaceutical company, a failed primary endpoint in a pivotal Phase 2/3 trial represents a material setback to a key development program that would significantly affect investor assessment of the company's pipeline and prospects. This does not fit neatly into the specific event categories (not a restatement, impairment, or litigation), making \"other_material\" the appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T03:09:58.600880+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3377,"accession_number":"0001689548-26-000053","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.85,"reasoning":"The disclosure reports that the Phase 2/3 POWER1 study of vormatrigine failed to meet its primary success measure in focal onset seizures, though secondary measures were met. The Company is pausing enrollment in the POWER2 study to reassess the program. For a clinical-stage biopharmaceutical company, a failed primary endpoint in a pivotal Phase 2/3 trial represents a material setback to a key development program that would significantly affect investor assessment of the company's pipeline and prospects. This does not fit neatly into the specific event categories (not a restatement, impairment, or litigation), making \"other_material\" the appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T03:09:58.600880+00:00","company_name":"Praxis Precision Medicines, Inc.","ticker":"PRAX","filing_date":"2026-06-01"}]}